John A. Bridgewater

Huntley Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 166 publications

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer.

EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer.

Journal: Translational oncology

Published: March 28, 2026

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial.

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial.

Journal: JAMA

Published: March 16, 2026

Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness.

Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness.

Journal: Trends in cancer

Published: February 25, 2026

Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials.

Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials.

Journal: JHEP reports : innovation in hepatology

Published: January 23, 2026

Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.

Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.

Journal: ESMO open

Published: January 12, 2026

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 09, 2026

Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer.

Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer.

Journal: The lancet. Gastroenterology & hepatology

Published: December 19, 2025

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

Journal: Journal for immunotherapy of cancer

Published: December 01, 2025

Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers.

Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers.

Journal: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]

Published: November 27, 2025

Isocitrate dehydrogenase mutations as potential tumour agnostic targets.

Isocitrate dehydrogenase mutations as potential tumour agnostic targets.

Journal: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]

Published: November 27, 2025

Showing 1-12 of 166

Last Updated: 09/26/2026